<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04447703</url>
  </required_header>
  <id_info>
    <org_study_id>20G.013</org_study_id>
    <secondary_id>2020-02556</secondary_id>
    <nct_id>NCT04447703</nct_id>
  </id_info>
  <brief_title>Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study</brief_title>
  <official_title>Technology-Enhanced Acceleration of Germline Evaluation for Therapy - The TARGET Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial performs user testing of a mobile-friendly patient history collection and genetic&#xD;
      education tool to improve healthcare providers' understanding of prostate cancer genetic&#xD;
      testing. This trial also compares traditional genetic counseling versus a web-based genetic&#xD;
      education (WBGE) tool to provide information about genetic testing to men with prostate&#xD;
      cancer. The WBGE tool has educational modules on genetic counseling and testing, as well as a&#xD;
      patient history collection tool to help providers learn which patients may carry genetic&#xD;
      mutations and may be considered for genetic counseling and genetic testing. The purpose of&#xD;
      this research is to use technology to deliver information on genetic testing for prostate&#xD;
      cancer to patients to help them decide whether or not to receive genetic testing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Perform user-testing of an education and patient history collection mobile tool among&#xD;
      medical oncologists, radiation oncologists, and urologists across study practice settings,&#xD;
      including Veterans Affairs to address genetic referral needs (n=10 providers).&#xD;
      (Provider-focused) II. Develop multimedia web-based pretest genetic education (WBGE) tool and&#xD;
      conduct a randomized trial of traditional genetic counseling (GC) (Arm 1) versus (vs.) WBGE&#xD;
      (Arm 2) for informed and timely uptake of genetic testing for men with lethal/predicted&#xD;
      lethal prostate cancer (PCA). (Patient-focused)&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      AIM I: Providers attend an interview over 1 hour to discuss how they would use the tool, then&#xD;
      receive the tool to test in their clinic for 2 weeks. After 2 weeks, providers discuss their&#xD;
      experience using the tool over 10-15 minutes. Providers have the option to use the tool for&#xD;
      up to 6 months and complete a brief survey about the benefits and limitations of the tool for&#xD;
      patient identification in Arm II.&#xD;
&#xD;
      AIM II: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I (TRADITIONAL GENETIC COUNSELING): Patients receive genetic counseling with a certified&#xD;
      genetic counselor in-person, by telehealth, or over the phone (according to patient&#xD;
      preference). Patients may then undergo genetic testing.&#xD;
&#xD;
      ARM II (WEB-BASED GENETIC EDUCATION): Patients receive a link to the web-based genetic&#xD;
      education tool online including all elements of genetic counseling in written modules and in&#xD;
      a series of professional videos. Patients may then undergo genetic testing. Patients may&#xD;
      cross-over to Arm I to see a genetic counselor.&#xD;
&#xD;
      After the completion of study, patients are followed up yearly for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Anticipated">September 2029</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>User Testing of the Provider Tool - (Aim I)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Provider perspectives will include: (1) whether the target population can use the tool in the way it was intended (i.e., to perform patient history collection to determine consideration for germline testing), and (2) interaction with this tool affects the user's cognitive representation of genetic testing for prostate cancer (PCA). To evaluate the first point, will collect initial information from participants regarding their experience with the guidelines for genetic testing and how they collect data on family history. Will evaluate participants' mental model for germline testing and how they identify suitable candidates before interaction with the tool. Will use a cognitive concept mapping technique, which can be used to formalize a person's cognitive representation for complex topics. Feedback from this testing will be used to iteratively refine the tool while it is being used by providers to identify patients randomized trial in Aim II.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decisional Conflict (Aim II)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will be assessed for non-inferiority between study arms. Evaluated using the O'Connor decisional conflict scale, which captures sub-scores over 16-questions for uncertainty, feeling of being informed, values clarity, support, and effective decision making on a 5-point Likert scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer Genetics Knowledge (Aim II)</measure>
    <time_frame>Up to 6 Months</time_frame>
    <description>Assessed using pre- and post-intervention surveys. Cancer genetics knowledge will be adapted from Erblich. et al (2005) for relevance to PCA genetics (23 True/False questions) (Cronbach's alpha = 0.92).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Testing Uptake (Aim II)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Assessed using pre-and post-intervention surveys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with Genetic Counseling or Web-Based Genetic Education (Aim II)</measure>
    <time_frame>After viewing the web tool</time_frame>
    <description>Will capture men's satisfaction with each arm using the Satisfaction with Genetic Counseling Scale at the end of pre-test genetic counseling or after viewing the web tool. This 6-item scale includes questions such as: &quot;My genetic counselor seemed to understand the stresses I was facing,&quot; and &quot;The genetic counseling session was valuable to me&quot; rated on a 5-point Likert scale (Cronbach's alpha 0.7-0.88). The questions will be adapted for web-based pretest genetic education such as &quot;This webtool addressed all of the concerns I had&quot; or &quot;The webtool was valuable to me&quot;.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Understanding of personal genetic test results (Aim II)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Assessed using pre- and post-intervention surveys.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sharing of genetic information with families (Aim II)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Assessed using pre- and post-intervention surveys.</description>
  </other_outcome>
  <other_outcome>
    <measure>Literacy (Aim II)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Assessed using pre- and post-intervention surveys.</description>
  </other_outcome>
  <other_outcome>
    <measure>Numeracy (Aim II)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Assessed using pre- and post-intervention surveys.</description>
  </other_outcome>
  <other_outcome>
    <measure>Diet (Aim II)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Assessed using pre- and post-intervention surveys.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity (Aim II)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Assessed using pre- and post-intervention surveys.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Biochemically Recurrent Prostate Carcinoma</condition>
  <condition>Metastatic Prostate Carcinoma</condition>
  <condition>Stage IIIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIC Prostate Cancer AJCC v8</condition>
  <condition>Stage IV Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Aim I (Interview)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Providers attend an interview over 1 hour to discuss how they would use the tool, then receive the tool to test in their clinic for 2 weeks. After 2 weeks, providers discuss their experience using the tool over 10-15 minutes. Providers have the option to use the tool for up to 6 months and complete a brief survey about the benefits and limitations of the tool for patient identification in Arm II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim II: Arm I (Genetic Counseling, Genetic Testing)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive genetic counseling with a certified genetic counselor in-person, by telehealth, or over the phone (according to patient preference). Patients may then undergo genetic testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a link to the web-based genetic education tool online including all elements of genetic counseling in written modules and in a series of professional videos. Patient may then undergo genetic testing. Patient may cross-over to Arm I to see a genetic counselor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>Attend Interview</description>
    <arm_group_label>Aim I (Interview)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Internet Based Intervention</intervention_name>
    <description>Use web-based genetic education tool online</description>
    <arm_group_label>Aim I (Interview)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Aim I (Interview)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic Counseling</intervention_name>
    <description>Receive in-person, telehealth, or over-the-phone genetic counseling</description>
    <arm_group_label>Aim II: Arm I (Genetic Counseling, Genetic Testing)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic Testing</intervention_name>
    <description>Undergo genetic testing</description>
    <arm_group_label>Aim II: Arm I (Genetic Counseling, Genetic Testing)</arm_group_label>
    <other_name>Genetic Analysis, Genetic Examination, Genetic Test, Genetic Testing, Genetic Testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Aim II: Arm I (Genetic Counseling, Genetic Testing)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic Counseling</intervention_name>
    <description>Receive in-person, telehealth, or over-the-phone genetic counseling</description>
    <arm_group_label>Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Internet-Based Intervention</intervention_name>
    <description>Use web-based genetic education tool online</description>
    <arm_group_label>Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic Testing</intervention_name>
    <description>Undergo genetic testing</description>
    <arm_group_label>Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)</arm_group_label>
    <other_name>Genetic Analysis, Genetic Examination, Genetic Test, Genetic Testing, Genetic Testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  AIM 1: Medical oncologists, radiation oncologists and urologists spanning Veterans&#xD;
             Affairs (VA), academic, and community settings&#xD;
&#xD;
          -  AIM 2: Any English speaking man &gt;= 18 with PCA who has computer and web-access and&#xD;
             meets any one of the following:&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  T3a or higher&#xD;
&#xD;
               -  Prostate specific antigen (PSA) &gt; 20&#xD;
&#xD;
               -  Grade group 4 or higher&#xD;
&#xD;
               -  Intraductal or cribriform histology&#xD;
&#xD;
               -  Biochemical recurrence&#xD;
&#xD;
               -  Ashkenazi Jewish ancestry&#xD;
&#xD;
               -  Family history criteria (see below) ** Family history: If any one of the&#xD;
                  following levels are met, the person is eligible:&#xD;
&#xD;
                    -  Level 1: &gt;= 1 close blood relative (first degree relative [FDR], second&#xD;
                       degree relative [SDR], third degree relative [TDR]) diagnosed with breast&#xD;
                       cancer =&lt; age 50 or the following cancers at any age: pancreatic, ovarian,&#xD;
                       or metastatic or intraductal/cribriform prostate cancer&#xD;
&#xD;
                    -  Level 2: &gt;= 2 close blood relatives (FDR, SDR, TDR) on same side of the&#xD;
                       family with breast or prostate cancer at any age&#xD;
&#xD;
                    -  Level 3: one brother, father, or &gt;= 2 family members (close blood relatives&#xD;
                       - FDR, SDR, TDR) on the same side of the family diagnosed with prostate&#xD;
                       cancer at &lt; 60&#xD;
&#xD;
                    -  Level 4: &gt;= 3 cancers on the same side of the family (especially if&#xD;
                       diagnosed =&lt; 50): bile duct, breast, colorectal, endometrial, gastric,&#xD;
                       kidney, melanoma, ovarian, pancreatic, prostate (grade groups 2-5 if known),&#xD;
                       small bowel, or urothelial&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Mental or cognitive impairment that interferes with ability to provide informed&#xD;
             consent&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Having had prior germline genetic testing for inherited cancer risk (pertains to aim&#xD;
             2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veda Giri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>October 25, 2022</last_update_submitted>
  <last_update_submitted_qc>October 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04447703
org study id: 20G.013
secondary id: 2020-02556
nct id: NCT04447703
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
This trial performs user testing of a mobile-friendly patient history collection and genetic
      education tool to improve healthcare providers' understanding of prostate cancer genetic
      testing. This trial also compares traditional genetic counseling versus a web-based genetic
      education (WBGE) tool to provide information about genetic testing to men with prostate
      cancer. The WBGE tool has educational modules on genetic counseling and testing, as well as a
      patient history collection tool to help providers learn which patients may carry genetic
      mutations and may be considered for genetic counseling and genetic testing. The purpose of
      this research is to use technology to deliver information on genetic testing for prostate
      cancer to patients to help them decide whether or not to receive genetic testing.
PRIMARY OBJECTIVES:

      I. Perform user-testing of an education and patient history collection mobile tool among
      medical oncologists, radiation oncologists, and urologists across study practice settings,
      including Veterans Affairs to address genetic referral needs (n=10 providers).
      (Provider-focused) II. Develop multimedia web-based pretest genetic education (WBGE) tool and
      conduct a randomized trial of traditional genetic counseling (GC) (Arm 1) versus (vs.) WBGE
      (Arm 2) for informed and timely uptake of genetic testing for men with lethal/predicted
      lethal prostate cancer (PCA). (Patient-focused)

      OUTLINE:

      AIM I: Providers attend an interview over 1 hour to discuss how they would use the tool, then
      receive the tool to test in their clinic for 2 weeks. After 2 weeks, providers discuss their
      experience using the tool over 10-15 minutes. Providers have the option to use the tool for
      up to 6 months and complete a brief survey about the benefits and limitations of the tool for
      patient identification in Arm II.

      AIM II: Patients are randomized to 1 of 2 arms.

      ARM I (TRADITIONAL GENETIC COUNSELING): Patients receive genetic counseling with a certified
      genetic counselor in-person, by telehealth, or over the phone (according to patient
      preference). Patients may then undergo genetic testing.

      ARM II (WEB-BASED GENETIC EDUCATION): Patients receive a link to the web-based genetic
      education tool online including all elements of genetic counseling in written modules and in
      a series of professional videos. Patients may then undergo genetic testing. Patients may
      cross-over to Arm I to see a genetic counselor.

      After the completion of study, patients are followed up yearly for up to 5 years.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Health Services Research
masking: None (Open Label)
measure: User Testing of the Provider Tool - (Aim I)
time frame: Up to 6 months
description: Provider perspectives will include: (1) whether the target population can use the tool in the way it was intended (i.e., to perform patient history collection to determine consideration for germline testing), and (2) interaction with this tool affects the user's cognitive representation of genetic testing for prostate cancer (PCA). To evaluate the first point, will collect initial information from participants regarding their experience with the guidelines for genetic testing and how they collect data on family history. Will evaluate participants' mental model for germline testing and how they identify suitable candidates before interaction with the tool. Will use a cognitive concept mapping technique, which can be used to formalize a person's cognitive representation for complex topics. Feedback from this testing will be used to iteratively refine the tool while it is being used by providers to identify patients randomized trial in Aim II.
measure: Decisional Conflict (Aim II)
time frame: Up to 6 months
description: Will be assessed for non-inferiority between study arms. Evaluated using the O'Connor decisional conflict scale, which captures sub-scores over 16-questions for uncertainty, feeling of being informed, values clarity, support, and effective decision making on a 5-point Likert scale
measure: Cancer Genetics Knowledge (Aim II)
time frame: Up to 6 Months
description: Assessed using pre- and post-intervention surveys. Cancer genetics knowledge will be adapted from Erblich. et al (2005) for relevance to PCA genetics (23 True/False questions) (Cronbach's alpha = 0.92).
measure: Genetic Testing Uptake (Aim II)
time frame: Up to 5 years
description: Assessed using pre-and post-intervention surveys
measure: Satisfaction with Genetic Counseling or Web-Based Genetic Education (Aim II)
time frame: After viewing the web tool
description: Will capture men's satisfaction with each arm using the Satisfaction with Genetic Counseling Scale at the end of pre-test genetic counseling or after viewing the web tool. This 6-item scale includes questions such as: "My genetic counselor seemed to understand the stresses I was facing," and "The genetic counseling session was valuable to me" rated on a 5-point Likert scale (Cronbach's alpha 0.7-0.88). The questions will be adapted for web-based pretest genetic education such as "This webtool addressed all of the concerns I had" or "The webtool was valuable to me".
measure: Understanding of personal genetic test results (Aim II)
time frame: Up to 5 years
description: Assessed using pre- and post-intervention surveys.
measure: Sharing of genetic information with families (Aim II)
time frame: Up to 5 years
description: Assessed using pre- and post-intervention surveys.
measure: Literacy (Aim II)
time frame: Up to 5 years
description: Assessed using pre- and post-intervention surveys.
measure: Numeracy (Aim II)
time frame: Up to 5 years
description: Assessed using pre- and post-intervention surveys.
measure: Diet (Aim II)
time frame: Up to 5 years
description: Assessed using pre- and post-intervention surveys.
measure: Physical activity (Aim II)
time frame: Up to 5 years
description: Assessed using pre- and post-intervention surveys.
arm group label: Aim I (Interview)
arm group type: Experimental
description: Providers attend an interview over 1 hour to discuss how they would use the tool, then receive the tool to test in their clinic for 2 weeks. After 2 weeks, providers discuss their experience using the tool over 10-15 minutes. Providers have the option to use the tool for up to 6 months and complete a brief survey about the benefits and limitations of the tool for patient identification in Arm II.
arm group label: Aim II: Arm I (Genetic Counseling, Genetic Testing)
arm group type: Active Comparator
description: Patients receive genetic counseling with a certified genetic counselor in-person, by telehealth, or over the phone (according to patient preference). Patients may then undergo genetic testing.
arm group label: Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)
arm group type: Experimental
description: Patients receive a link to the web-based genetic education tool online including all elements of genetic counseling in written modules and in a series of professional videos. Patient may then undergo genetic testing. Patient may cross-over to Arm I to see a genetic counselor.
intervention type: Other
intervention name: Interview
description: Attend Interview
arm group label: Aim I (Interview)
intervention type: Other
intervention name: Internet Based Intervention
description: Use web-based genetic education tool online
arm group label: Aim I (Interview)
intervention type: Other
intervention name: Survey Administration
description: Ancillary Studies
arm group label: Aim I (Interview)
intervention type: Other
intervention name: Genetic Counseling
description: Receive in-person, telehealth, or over-the-phone genetic counseling
arm group label: Aim II: Arm I (Genetic Counseling, Genetic Testing)
intervention type: Genetic
intervention name: Genetic Testing
description: Undergo genetic testing
arm group label: Aim II: Arm I (Genetic Counseling, Genetic Testing)
other name: Genetic Analysis, Genetic Examination, Genetic Test, Genetic Testing, Genetic Testing
intervention type: Other
intervention name: Survey Administration
description: Ancillary Studies
arm group label: Aim II: Arm I (Genetic Counseling, Genetic Testing)
intervention type: Other
intervention name: Genetic Counseling
description: Receive in-person, telehealth, or over-the-phone genetic counseling
arm group label: Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)
intervention type: Other
intervention name: Internet-Based Intervention
description: Use web-based genetic education tool online
arm group label: Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)
intervention type: Genetic
intervention name: Genetic Testing
description: Undergo genetic testing
arm group label: Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)
other name: Genetic Analysis, Genetic Examination, Genetic Test, Genetic Testing, Genetic Testing
intervention type: Other
intervention name: Survey Administration
description: Ancillary Studies
arm group label: Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
last name: Veda Giri, MD
role: Principal Investigator
affiliation: Thomas Jefferson University
facility: 
country: United States
responsible party type: Sponsor
mesh term: Carcinoma
mesh term: Prostatic Neoplasms